

Shi Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9659506/publications.pdf>

Version: 2024-02-01

15
papers

438
citations

687363

13
h-index

996975

15
g-index

15
all docs

15
docs citations

15
times ranked

940
citing authors

#	ARTICLE	IF	CITATIONS
1	Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells. <i>Nature Communications</i> , 2017, 8, 15102.	12.8	88
2	HOTTIP-dependent R-loop formation regulates CTCF boundary activity and TAD integrity in leukemia. <i>Molecular Cell</i> , 2022, 82, 833-851.e11.	9.7	48
3	ASXL1 plays an important role in erythropoiesis. <i>Scientific Reports</i> , 2016, 6, 28789.	3.3	38
4	ASXL1 interacts with the cohesin complex to maintain chromatid separation and gene expression for normal hematopoiesis. <i>Science Advances</i> , 2017, 3, e1601602.	10.3	35
5	TET2 Loss Dysregulates the Behavior of Bone Marrow Mesenchymal Stromal Cells and Accelerates Tet2-Driven Myeloid Malignancy Progression. <i>Stem Cell Reports</i> , 2018, 10, 166-179.	4.8	34
6	Loss of ASXL1 in the bone marrow niche dysregulates hematopoietic stem and progenitor cell fates. <i>Cell Discovery</i> , 2018, 4, 4.	6.7	28
7	ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis. <i>Leukemia</i> , 2019, 33, 1287-1291.	7.2	26
8	Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy. <i>Journal of Clinical Investigation</i> , 2018, 128, 5383-5398.	8.2	25
9	The catalytic activity of TET2 is essential for its myeloid malignancy-suppressive function in hematopoietic stem/progenitor cells. <i>Leukemia</i> , 2016, 30, 1784-1788.	7.2	24
10	Loss of Asxl2 leads to myeloid malignancies in mice. <i>Nature Communications</i> , 2017, 8, 15456.	12.8	23
11	Tet2 Regulates Osteoclast Differentiation by Interacting with Runx1 and Maintaining Genomic 5-Hydroxymethylcytosine (5hmC). <i>Genomics, Proteomics and Bioinformatics</i> , 2018, 16, 172-186.	6.9	22
12	Reduced BAP1 activity prevents ASXL1 truncation-driven myeloid malignancy in vivo. <i>Leukemia</i> , 2018, 32, 1834-1837.	7.2	20
13	Loss of Asxl1 Alters Self-Renewal and Cell Fate of Bone Marrow Stromal Cells, Leading to Bohring-Opitz-like Syndrome in Mice. <i>Stem Cell Reports</i> , 2016, 6, 914-925.	4.8	18
14	INTS11 regulates hematopoiesis by promoting PRC2 function. <i>Science Advances</i> , 2021, 7, eabh1684.	10.3	6
15	Characteristics of myeloid sarcoma in mice and patients with TET2 deficiency. <i>Oncology Letters</i> , 2020, 19, 3789-3798.	1.8	3